Literature DB >> 19660432

Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice.

T van Es1, G H M van Puijvelde, O H Ramos, F M E Segers, L A Joosten, W B van den Berg, I M Michon, P de Vos, Th J C van Berkel, J Kuiper.   

Abstract

Atherosclerosis is an inflammatory disease characterized by the influx of macrophages and T cells and IL-17 may connect innate and adaptive immune responses involved in atherogenesis. We investigated the role of IL-17 receptor signaling in atherosclerosis and transplanted LDLr deficient recipient mice with IL-17R deficient bone marrow. Induction of atherosclerosis by Western-type diet induced a 46% reduction in lesion size in the aortic root and the plaque composition revealed no significant changes in collagen content and neutrophil counts, but a reduction in mast cell number and an increase in macrophage number. In addition, we observed a decrease in anti-oxLDL antibodies of the IgG class upon IL-17R BMT, while introduction of IL-17R deficient bone marrow resulted in a reduced IL-6 production and an increased IL-10 production. In conclusion, signaling via the IL-17 receptor in bone marrow derived cells enhances the process of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19660432     DOI: 10.1016/j.bbrc.2009.07.152

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  62 in total

1.  CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice.

Authors:  Christian Weber; Svenja Meiler; Yvonne Döring; Miriam Koch; Maik Drechsler; Remco T A Megens; Zuzanna Rowinska; Kiril Bidzhekov; Caroline Fecher; Eliana Ribechini; Marc A M J van Zandvoort; Christoph J Binder; Ivett Jelinek; Mihail Hristov; Louis Boon; Steffen Jung; Thomas Korn; Manfred B Lutz; Irmgard Förster; Martin Zenke; Thomas Hieronymus; Tobias Junt; Alma Zernecke
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  Attenuated atherosclerotic lesions in apoE-Fcγ-chain-deficient hyperlipidemic mouse model is associated with inhibition of Th17 cells and promotion of regulatory T cells.

Authors:  Hang Pong Ng; Ramona L Burris; Shanmugam Nagarajan
Journal:  J Immunol       Date:  2011-10-31       Impact factor: 5.422

Review 3.  Interleukin 17 in vascular inflammation.

Authors:  Sibylle von Vietinghoff; Klaus Ley
Journal:  Cytokine Growth Factor Rev       Date:  2010-11-12       Impact factor: 7.638

4.  The IL-17A/IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment.

Authors:  Matthew J Butcher; Breanne N Gjurich; Tracy Phillips; Elena V Galkina
Journal:  Circ Res       Date:  2012-02-02       Impact factor: 17.367

Review 5.  Atherosclerosis and the role of immune cells.

Authors:  Fulya Ilhan; Sevgi Tas Kalkanli
Journal:  World J Clin Cases       Date:  2015-04-16       Impact factor: 1.337

Review 6.  The immune system in atherosclerosis.

Authors:  Göran K Hansson; Andreas Hermansson
Journal:  Nat Immunol       Date:  2011-03       Impact factor: 25.606

Review 7.  Adaptive immunity in atherogenesis: new insights and therapeutic approaches.

Authors:  Andrew H Lichtman; Christoph J Binder; Sotirios Tsimikas; Joseph L Witztum
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

Review 8.  Inflammation and immune system interactions in atherosclerosis.

Authors:  Bart Legein; Lieve Temmerman; Erik A L Biessen; Esther Lutgens
Journal:  Cell Mol Life Sci       Date:  2013-02-21       Impact factor: 9.261

9.  CXCR6 regulates the recruitment of pro-inflammatory IL-17A-producing T cells into atherosclerotic aortas.

Authors:  Matthew J Butcher; Chih-I Wu; Tayab Waseem; Elena V Galkina
Journal:  Int Immunol       Date:  2015-11-27       Impact factor: 4.823

10.  Stat3β mitigates development of atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Jihyun Lee; William M Baldwin; Chih-Yuan Lee; Stephen Desiderio
Journal:  J Mol Med (Berl)       Date:  2013-04-26       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.